Condition
Colon/Rectal Cancer
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Terminated2
Withdrawn1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01163526Terminated
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
NCT01137162Terminated
Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors
NCT00532909Phase 1Completed
Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer
NCT01031056Withdrawn
Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers
Showing all 4 trials